Cibus (CBUS) Stock: Buy, Sell, or Hold?
CBUS - Cibus, Inc. Class A Common Stock
$1.41
0.01 (0.71%)
▲
5d:
+6.82%
30d:
-6.0%
90d:
-22.1%
BUY
MODERATE Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 12, 2026
18d
Get Alerted When CBUS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CBUS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CBUS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CBUS is currently trading at $1.41, which is considered slightly low relative to its 30-day fair value range of $1.40 to $1.62.
Technical Outlook: Technically, CBUS is showing sideways momentum. Immediate support is located at $1.26, while resistance sits at $1.57.
Market Sentiment: CBUS scores 61/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $14.33 (+916.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CBUS is showing sideways momentum. Immediate support is located at $1.26, while resistance sits at $1.57.
Market Sentiment: CBUS scores 61/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $14.33 (+916.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.40 -
$1.62
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (61/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 916.5% below Wall St target ($14.33)
- BULLISH: Bottoming setup score 61/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$1.40 -
$1.62
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1.26
Resistance Level
$1.57
Current Trend
Sideways
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.22
Wall Street Target
$14.33
(+916.5%)
Revenue Growth (YoY)
6.5%
Share & Embed Analysis
Last updated: October 23, 2026 8:10 PM ET
Data refreshes hourly during market hours. Next update: 9:10 PM
Data refreshes hourly during market hours. Next update: 9:10 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CBUS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$295 | 64 BUY |
|
PRAX
Praxis Precision Medicin… |
STRONG BUY
20 analysts |
$650 | 65 BUY |
|
REGN
Regeneron Pharmaceutical… |
BUY
28 analysts |
$864 | 35 SELL |
|
ELVN
Enliven Therapeutics Inc. |
STRONG BUY
14 analysts |
$74 | 65 BUY |
|
ACAD
ACADIA Pharmaceuticals I… |
STRONG BUY
20 analysts |
$31 | 61 BUY |
